Ugur Eskiocak
Chief Executive Officer & Co-Founder Voro Therapeutics
Seminars
Wednesday 9th September 2026
Tumor Selectivity Strategies Across Multispecifics, TCEs, & ADCs: What Have we Learnt so Far?
11:40 am
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
